注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01(汉利康)、赫赛汀(曲妥珠单抗)生物类似药HLX02、修美乐(阿达木单抗)生物类似药HLX03和安维汀(贝伐珠单抗)生物类似药HLX04以及候选生物创新药,包括HLX06(一种新型VEGFR2抑制剂)、HLX07(一种EGFR抑制剂)、HLX10(一种新型PD-1抑制剂)、HLX20(一种新型PD-L1抑制剂)及HLX22(一种新型HER2抑制剂)等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Xiaohui Guan | 53 | 2018 | Non-Executive Director |
Lik Yuen Chan | 56 | 2019 | Independent Non-Executive Director |
Tak Young So | 53 | 2019 | Independent Non-Executive Director |
Ruilin Song | 60 | 2019 | Independent Non-Executive Director |
Guoping Zhao | 75 | 2019 | Independent Non-Executive Director |
Deli Kong | 50 | 2016 | Supervisor |
Qiyu Chen | 52 | 2013 | Non-Executive Director |
Rongli Feng | 49 | 2020 | Chairman of Supervisory Board |
Alberto Mantovani | - | 2023 | Member of Scientific Advisory Board |
Yifang Wu | 55 | 2015 | Non-Executive Director |
David R. Gandara | 76 | 2023 | Member of Scientific Advisory Board |
Abul K. Abbas | - | 2023 | Member of Scientific Advisory Board |
K. Christopher Garcia | - | 2023 | Member of Scientific Advisory Board |
Yexing Yuan | 40 | 2023 | Supervisor |
Deyong Wen | 53 | 2022 | Non-Executive Director |
Xingli Wang | - | 2023 | Non-Executive Director |
Yangxin Fu | - | - | Member of Scientific Advisory Board |
Lixin Zhang | - | - | Member of Scientific Advisory Board |
Wenjie Zhang | 57 | 2019 | Executive Chairman of the Board |
Jun Zhu | 45 | 2021 | CEO, CFO & Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核